Rosolová H, Podlipný J
Centrum preventivní kardiologie II. interní kliniky Lékarské fakulty UK a FN v Plzni.
Vnitr Lek. 2009 Jul-Aug;55(7-8):650-2.
Anxiety and depressive behavioural disorders often occur concomitantly and their incidence in the general population as well as in chronically ill is higher than anticipated. Pilsen study of male and female patients (N = 1,050) selected from a population-based sample of the primary prevention survey PILS III (Pilsen Longitudinal Study III) had proven an existence of associations between depressive behavioural disorder and metabolic syndrome (MS). Depressive disorders were nearly twice as frequent in patients with MS compared to individuals without MS (RR = 1.85; CI: 1.11-3.10). Patients with psychiatric disorders were excreting more cortisol in the urine than individuals without psychiatric disorders, while there was no difference in the excretion ofcatecholamines and serotonin. Our results provide an indirect evidence for the hypothesis suggesting that increased activation of the sympathoadrenal axis could be pathophysiologically involved in the concomitant occurrence of the typical MS risk factors and depressed mood. Anxiety and depressive disorders are linked to higher cardiometabolic risk, higher incidence of acute cardiovascular events as well as poorer prognosis for cardiac patients; they are comorbid to a range of other chronic internal diseases. The association between cardiovascular disease, diabetes and psychiatric disorders is bilateral, i.e. patients with anxiety and depression experience cardiovascular events more frequently, and the patients with type 2 diabetes and cardiometabolic diseases suffer more frequently from anxious-depressive disorder. In clinical practice, we should search for anxious-depressive disorders. At present, the patients with anxiety or depression should be considered in the primary disease prevention as patients at high risk of atherosclerotic vascular diseases as well as MS and type 2 diabetes. Treatment of these diseases as part of secondary prevention in patients with anxiety and depression must be more rigorous and intensive than in patients without these psychiatric disorders.
焦虑和抑郁行为障碍常常同时出现,其在普通人群以及慢性病患者中的发病率高于预期。对从基于人群的初级预防调查PILS III(皮尔森纵向研究III)样本中选取的1050名男性和女性患者进行的皮尔森研究,已证实抑郁行为障碍与代谢综合征(MS)之间存在关联。与无MS的个体相比,MS患者中抑郁障碍的发生率几乎高出一倍(相对风险 = 1.85;置信区间:1.11 - 3.10)。患有精神疾病的患者尿中皮质醇排泄量比无精神疾病的个体更多,而儿茶酚胺和血清素的排泄量则无差异。我们的结果为以下假设提供了间接证据,即交感肾上腺轴的激活增加可能在病理生理上参与了典型MS危险因素与情绪低落的同时出现。焦虑和抑郁障碍与更高的心脏代谢风险、急性心血管事件的更高发生率以及心脏病患者更差的预后相关;它们还与一系列其他慢性内科疾病共病。心血管疾病、糖尿病和精神疾病之间的关联是双向的,即焦虑和抑郁患者更频繁地发生心血管事件,而2型糖尿病和心脏代谢疾病患者更频繁地患有焦虑抑郁障碍。在临床实践中,我们应筛查焦虑抑郁障碍。目前,在原发性疾病预防中,应将焦虑或抑郁患者视为动脉粥样硬化性血管疾病以及MS和2型糖尿病的高危患者。作为焦虑和抑郁患者二级预防一部分的这些疾病的治疗,必须比无这些精神疾病的患者更严格、更强化。